Metraipolis › archive › dc_31e507ada56f

Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy — Europe PMC PMID:42514926

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42514926
DOI
10.3390/pharmaceutics18070848
License (as archived)
solo-consultazione
Archived
2026-10-18T07:59:22.681Z
SHA-256 of the archived text
132d3f1d2cac992b01c8debaba1c07736f1eb11e8d1e6b2624f41ce59dd226cc
Stable URL of this page
https://metraipolis.com/documento/dc_31e507ada56f

How to cite

Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy — Europe PMC PMID:42514926 — Europe PMC (en), https://europepmc.org/article/MED/42514926 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_31e507ada56f (Metraipolis archive dc_31e507ada56f, sha256 132d3f1d2cac992b01c8debaba1c07736f1eb11e8d1e6b2624f41ce59dd226cc)
BibTeX
@misc{dc31e507ada56f,
  title = {Breaking the Silent Barrier: Engineering Antibodies for Brain-Targeted Rabies Immunotherapy — Europe PMC PMID:42514926},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42514926},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_31e507ada56f; sha256 132d3f1d2cac992b01c8debaba1c07736f1eb11e8d1e6b2624f41ce59dd226cc},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42514926. Agents can read the archived copy with the MCP tool read_document.